Marshall Wace LLP Invests $253,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Marshall Wace LLP bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 3,979 shares of the specialty pharmaceutical company’s stock, valued at approximately $253,000.

Other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $65,000. Ridgewood Investments LLC acquired a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $85,000. SG Americas Securities LLC acquired a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $106,000. O Shaughnessy Asset Management LLC acquired a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $218,000. Finally, XTX Topco Ltd purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth $207,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $63.38, for a total value of $697,180.00. Following the sale, the chief operating officer now owns 671,620 shares in the company, valued at $42,567,275.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 25,757 shares of company stock worth $1,626,762 over the last 90 days. 12.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a report on Friday. They issued an “overweight” rating and a $68.00 price target for the company. Truist Financial reaffirmed a “hold” rating and issued a $60.00 price target (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Finally, Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $77.00.

ANI Pharmaceuticals Stock Up 3.7 %

ANIP opened at $57.14 on Friday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The company has a fifty day moving average of $59.43 and a two-hundred day moving average of $62.72. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 35.71 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the previous year, the company earned $1.06 earnings per share. The firm’s revenue for the quarter was up 18.5% on a year-over-year basis. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.